TG Therapeutics, Inc. is a biopharmaceutical company based in Edison, NJ. They are focused on developing innovative therapies for various diseases, including multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), and marginal zone lymphoma (MZL). Their approved product, BRIUMVI, is indicated for the treatment of relapsing forms of MS in adults. TG Therapeutics is committed to advancing scientific research and collaborating with medical professionals to improve patient outcomes.
With a strong leadership team and a robust pipeline of potential therapies, TG Therapeutics is dedicated to making a significant impact in the field of healthcare. They prioritize patient safety and efficacy in their approach to drug development, and their dedication to scientific excellence is evident in their numerous publications and ongoing clinical trials. As a company, TG Therapeutics is driven by a fearless pursuit of innovative solutions and welcomes collaboration with medical professionals and researchers in their mission to improve the lives of patients.
Generated from the website